These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 16052206)

  • 1. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL.
    Sondhi D; Peterson DA; Giannaris EL; Sanders CT; Mendez BS; De B; Rostkowski AB; Blanchard B; Bjugstad K; Sladek JR; Redmond DE; Leopold PL; Kaminsky SM; Hackett NR; Crystal RG
    Gene Ther; 2005 Nov; 12(22):1618-32. PubMed ID: 16052206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis.
    Crystal RG; Sondhi D; Hackett NR; Kaminsky SM; Worgall S; Stieg P; Souweidane M; Hosain S; Heier L; Ballon D; Dinner M; Wisniewski K; Kaplitt M; Greenwald BM; Howell JD; Strybing K; Dyke J; Voss H
    Hum Gene Ther; 2004 Nov; 15(11):1131-54. PubMed ID: 15610613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates.
    Hackett NR; Redmond DE; Sondhi D; Giannaris EL; Vassallo E; Stratton J; Qiu J; Kaminsky SM; Lesser ML; Fisch GS; Rouselle SD; Crystal RG
    Hum Gene Ther; 2005 Dec; 16(12):1484-503. PubMed ID: 16390279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral-mediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP-I to the mouse central nervous system.
    Haskell RE; Hughes SM; Chiorini JA; Alisky JM; Davidson BL
    Gene Ther; 2003 Jan; 10(1):34-42. PubMed ID: 12525835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis.
    Sondhi D; Johnson L; Purpura K; Monette S; Souweidane MM; Kaplitt MG; Kosofsky B; Yohay K; Ballon D; Dyke J; Kaminksy SM; Hackett NR; Crystal RG
    Hum Gene Ther Methods; 2012 Oct; 23(5):324-35. PubMed ID: 23131032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector.
    Sondhi D; Hackett NR; Peterson DA; Stratton J; Baad M; Travis KM; Wilson JM; Crystal RG
    Mol Ther; 2007 Mar; 15(3):481-91. PubMed ID: 17180118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA.
    Worgall S; Sondhi D; Hackett NR; Kosofsky B; Kekatpure MV; Neyzi N; Dyke JP; Ballon D; Heier L; Greenwald BM; Christos P; Mazumdar M; Souweidane MM; Kaplitt MG; Crystal RG
    Hum Gene Ther; 2008 May; 19(5):463-74. PubMed ID: 18473686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysosomal degradation of cholecystokinin-(29-33)-amide in mouse brain is dependent on tripeptidyl peptidase-I: implications for the degradation and storage of peptides in classical late-infantile neuronal ceroid lipofuscinosis.
    Bernardini F; Warburton MJ
    Biochem J; 2002 Sep; 366(Pt 2):521-9. PubMed ID: 12038963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis.
    Sondhi D; Peterson DA; Edelstein AM; del Fierro K; Hackett NR; Crystal RG
    Exp Neurol; 2008 Sep; 213(1):18-27. PubMed ID: 18639872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and analysis of CLN2 variants in CHO cells: Q100R represents a polymorphism, and G389E and R447H represent loss-of-function mutations.
    Lin L; Lobel P
    Hum Mutat; 2001 Aug; 18(2):165. PubMed ID: 11462245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis.
    Passini MA; Dodge JC; Bu J; Yang W; Zhao Q; Sondhi D; Hackett NR; Kaminsky SM; Mao Q; Shihabuddin LS; Cheng SH; Sleat DE; Stewart GR; Davidson BL; Lobel P; Crystal RG
    J Neurosci; 2006 Feb; 26(5):1334-42. PubMed ID: 16452657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurological deterioration in late infantile neuronal ceroid lipofuscinosis.
    Worgall S; Kekatpure MV; Heier L; Ballon D; Dyke JP; Shungu D; Mao X; Kosofsky B; Kaplitt MG; Souweidane MM; Sondhi D; Hackett NR; Hollmann C; Crystal RG
    Neurology; 2007 Aug; 69(6):521-35. PubMed ID: 17679671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lysosomal degradation of neuromedin B is dependent on tripeptidyl peptidase-I: evidence for the impairment of neuropeptide degradation in late-infantile neuronal ceroid lipofuscinosis.
    Kopan S; Sivasubramaniam U; Warburton MJ
    Biochem Biophys Res Commun; 2004 Jun; 319(1):58-65. PubMed ID: 15158442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in classical late infantile neuronal ceroid lipofuscinosis disrupt transport of tripeptidyl-peptidase I to lysosomes.
    Steinfeld R; Steinke HB; Isbrandt D; Kohlschütter A; Gärtner J
    Hum Mol Genet; 2004 Oct; 13(20):2483-91. PubMed ID: 15317752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. R208X mutation in CLN2 gene associated with reduced cerebrospinal fluid pterins in a girl with classic late infantile neuronal ceroid lipofuscinosis.
    Barisić N; Logan P; Pikija S; Skarpa D; Blau N
    Croat Med J; 2003 Aug; 44(4):489-93. PubMed ID: 12950156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis.
    Griffey M; Macauley SL; Ogilvie JM; Sands MS
    Mol Ther; 2005 Sep; 12(3):413-21. PubMed ID: 15979943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation of the glycosylated asparagine residue 286 in human CLN2 protein results in loss of enzymatic activity.
    Tsiakas K; Steinfeld R; Storch S; Ezaki J; Lukacs Z; Kominami E; Kohlschütter A; Ullrich K; Braulke T
    Glycobiology; 2004 Apr; 14(4):1C-5C. PubMed ID: 14736728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of endopeptidase activity of tripeptidyl peptidase-I/CLN2 protein which is deficient in classical late infantile neuronal ceroid lipofuscinosis.
    Ezaki J; Takeda-Ezaki M; Oda K; Kominami E
    Biochem Biophys Res Commun; 2000 Feb; 268(3):904-8. PubMed ID: 10679303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural organization and sequence of CLN2, the defective gene in classical late infantile neuronal ceroid lipofuscinosis.
    Liu CG; Sleat DE; Donnelly RJ; Lobel P
    Genomics; 1998 Jun; 50(2):206-12. PubMed ID: 9653647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tripeptidyl-peptidase I in health and disease.
    Golabek AA; Kida E
    Biol Chem; 2006 Aug; 387(8):1091-9. PubMed ID: 16895480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.